Abstract
Indole-3-carbinol (I3C) and its oligomeric derivatives have been widely studied for their chemopreventive and chemotherapeutic properties. We have previously shown that the I3C cyclic tetrameric derivative CTet inhibits breast cancer cell proliferation in vitro and in xenotrasplanted tumor. Here we report the antitumoral activity of a mixture of tri- and tetrameric cyclic I3C derivatives (CTr/CTet) both in vitro (MCF-7 and MDA-MB-231 breast cancer cell lines) and in vivo in a tumor xenograft model. CTr/CTet mixture avoids the low solubility drawbacks of CTet, thus favouring its solubilization, and reducing purification process, time and costs. CTr/CTet mixture has been shown to inhibit breast cancer cell proliferation (IC50 = 1.3 and 1.6 μg/ml in MCF-7 and MDAMB- 231, respectively) inducing the G0/1 cell cycle phase accumulation. The main molecular events related to CTr/CTet activity are the overexpression of p21, p27 and GADD45A, nuclear translocation of FOXO3a, inhibition of Akt activity and downregulation of estrogen receptor. In vivo, the growth of xenotransplanted tumor has been inhibited and the pro-tumoral low molecular weight cyclin E downregulation has been detected. Our data indicate that CTr/CTet is a potential anticancer combination agent for both hormoneresponsive and triple-negative breast tumors.
Keywords: Akt, Breast Cancer, FOXO3a, GADD45A, I3C cyclic derivatives, LMW cyclin E, CTr/CTet, p21/CDKN1A, p27/CDKN1B
Anti-Cancer Agents in Medicinal Chemistry
Title:Antitumoral Activity of Indole-3-carbinol Cyclic tri- and Tetrameric Derivatives Mixture in Human Breast Cancer Cells: In Vitro and In Vivo Studies
Volume: 13 Issue: 4
Author(s): Giorgio Brandi, Alessandra Fraternale, Simone Lucarini, Mirko Paiardini, Mauro De Santi, Barbara Cervasi, Maria F. Paoletti, Luca Galluzzi, Andrea Duranti and Mauro Magnani
Affiliation:
Keywords: Akt, Breast Cancer, FOXO3a, GADD45A, I3C cyclic derivatives, LMW cyclin E, CTr/CTet, p21/CDKN1A, p27/CDKN1B
Abstract: Indole-3-carbinol (I3C) and its oligomeric derivatives have been widely studied for their chemopreventive and chemotherapeutic properties. We have previously shown that the I3C cyclic tetrameric derivative CTet inhibits breast cancer cell proliferation in vitro and in xenotrasplanted tumor. Here we report the antitumoral activity of a mixture of tri- and tetrameric cyclic I3C derivatives (CTr/CTet) both in vitro (MCF-7 and MDA-MB-231 breast cancer cell lines) and in vivo in a tumor xenograft model. CTr/CTet mixture avoids the low solubility drawbacks of CTet, thus favouring its solubilization, and reducing purification process, time and costs. CTr/CTet mixture has been shown to inhibit breast cancer cell proliferation (IC50 = 1.3 and 1.6 μg/ml in MCF-7 and MDAMB- 231, respectively) inducing the G0/1 cell cycle phase accumulation. The main molecular events related to CTr/CTet activity are the overexpression of p21, p27 and GADD45A, nuclear translocation of FOXO3a, inhibition of Akt activity and downregulation of estrogen receptor. In vivo, the growth of xenotransplanted tumor has been inhibited and the pro-tumoral low molecular weight cyclin E downregulation has been detected. Our data indicate that CTr/CTet is a potential anticancer combination agent for both hormoneresponsive and triple-negative breast tumors.
Export Options
About this article
Cite this article as:
Brandi Giorgio, Fraternale Alessandra, Lucarini Simone, Paiardini Mirko, De Santi Mauro, Cervasi Barbara, F. Paoletti Maria, Galluzzi Luca, Duranti Andrea and Magnani Mauro, Antitumoral Activity of Indole-3-carbinol Cyclic tri- and Tetrameric Derivatives Mixture in Human Breast Cancer Cells: In Vitro and In Vivo Studies, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (4) . https://dx.doi.org/10.2174/1871520611313040014
DOI https://dx.doi.org/10.2174/1871520611313040014 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design Properties and Therapeutic Potential of Transient Receptor Potential Channels with Putative Roles in Adversity: Focus on TRPC5, TRPM2 and TRPA1
Current Drug Targets Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Doripenem: A New Addition to the Carbapenem Class of Antimicrobials
Recent Patents on Anti-Infective Drug Discovery Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design Current Therapeutic Options for the Treatment of Juvenile Idiopathic Arthritis
Current Rheumatology Reviews Recent Progress in Discovery and Development of Antimitotic Agents
Anti-Cancer Agents in Medicinal Chemistry In vivo Radiosensitization of Human Glioma U87 Cells Induced by Upregulated Expression of DUSP-2 after Treatment with Curcumin
Current Signal Transduction Therapy Induction of Thyroid Neoplasm Following Plant Medicine Marine Algae (Sargassum): A Rare Case and Review of the Literature
Current Pharmaceutical Biotechnology Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier
Current Medicinal Chemistry Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Biotransformations of Prenylated Hop Flavonoids for Drug Discovery and Production
Current Drug Metabolism Establishment of Novel Cells Stably Secreting Various Human IL-18 Recombinant Proteins
Current Pharmaceutical Biotechnology Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Monoclonal Antibody-based Genetic Immunotherapy
Current Gene Therapy HSF1 as a Cancer Biomarker and Therapeutic Target
Current Cancer Drug Targets Ultrasonic Elasticity Imaging as a Tool for Breast Cancer Diagnosis and Research
Current Medical Imaging Ethical Implications of Pharmacogenetics: Shaping the Future of the Field
Current Pharmacogenomics